O fator estimulador de colônias granulocitárias (G-CSF) para isquemia cerebral: uma nova aplicação terapêutica?

AUTOR(ES)

Maset, Angelo Luiz, Duarte, Kleber P., Greco, Oswaldo Tadeu

FONTE

Revista Brasileira de Hematologia e Hemoterapia

DATA DE PUBLICAÇÃO

2007-12

RESUMO

G-CSF is a FDA-approved drug, commonly utilized in neutropenic patients, long knows for its anti-inflammatory and angiogenic properties and also for its capacity to mobilize stem cells, hematopoiethic and endogen precursors and progenitor cells. Recently neuroprotective effects have been shown in animals and humans and there are publications mentioning its potential therapeutic role in focal ischemia (medial cerebral artery territory). We describe a case of a 74-year-old male patient, victim of a subarachnoid hemorrhage and brain ischemia due to bilateral involvement of medial cerebral arteries and vertebrobasilar vasospasms (overall ischemia), who was submitted to G-C5F therapy. G-CSF did not cause adverse effects, mobilized cells (as was seen by the exponential increase in leukocytes) and possibly contributed to a progressive clinical improvement confirmed using GCS and NIHSS scales. Clinical improvements did not reflect in eithrt CT, MNR or SPECT examinations. This initial experience opens the perspective for G-CSF studies in brain ischemia.

Documentos Relacionados

• Neonatal sepsis with neutropenia: granulocytecolony stimulating factor (G-CSF)
• Neonatal sepsis with neutropenia: granulocyte-colony stimulating factor (G-CSF)
• Close Association between Clearance of Recombinant Human Granulocyte Colony-Stimulating Factor (G-CSF) and G-CSF Receptor on Neutrophils in Cancer Patients
• O G-CSF na terapia do acidente vascular cerebral
• Mononuclear cells from umbilical cord blood and from granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood. Analysis of proliferation and apoptosis in vitro